histone deacetylase 2

Target id: 2616

Nomenclature: histone deacetylase 2

Family: 3.5.1.- Histone deacetylases (HDACs)

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: OFF :     Currently no data for histone deacetylase 2 in GtoImmuPdb

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 488 6q21 HDAC2 histone deacetylase 2
Mouse - 488 10 B1 Hdac2 histone deacetylase 2
Rat - - 20q12 Hdac2 histone deacetylase 2
Previous and Unofficial Names
RPD3 | YAF1
Database Links
BRENDA
CATH/Gene3D
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
GenitoUrinary Development Molecular Anatomy Project
Human Protein Atlas
KEGG Enzyme
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Enzyme Reaction
EC Number: 3.5.1.98

Download all structure-activity data for this target as a CSV file

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
romidepsin Hs Inhibition 10.4 pKi 2
pKi 10.4 (Ki 3.8x10-11 M) [2]
apicidin Hs Inhibition 9.9 pKi 2
pKi 9.9 (Ki 1.2x10-10 M) [2]
trichostatin A Hs Inhibition 9.2 pKi 2
pKi 9.2 (Ki 6.5x10-10 M) [2]
belinostat Hs Inhibition 9.1 pKi 2
pKi 9.1 (Ki 8.5x10-10 M) [2]
dacinostat Hs Inhibition 8.9 pKi 2
pKi 8.9 (Ki 1.4x10-9 M) [2]
vorinostat Hs Inhibition 8.8 pKi 2
pKi 8.8 (Ki 1.6x10-9 M) [2]
scriptaid Hs Inhibition 8.7 pKi 2
pKi 8.7 (Ki 2.2x10-9 M) [2]
givinostat Hs Inhibition 8.5 pKi 2
pKi 8.5 (Ki 3x10-9 M) [2]
mocetinostat Hs Inhibition 7.5 pKi 2
pKi 7.5 (Ki 3.4x10-8 M) [2]
entinostat Hs Inhibition 7.2 pKi 2
pKi 7.2 (Ki 6.5x10-8 M) [2]
tacedinaline Hs Inhibition 6.8 pKi 2
pKi 6.8 (Ki 1.5x10-7 M) [2]
panobinostat Hs Inhibition 8.5 pEC50 7
pEC50 8.5 (EC50 3x10-9 M) [7]
givinostat Hs Inhibition 7.3 pEC50 7
pEC50 7.3 (EC50 5.6x10-8 M) [7]
apicidin Hs Inhibition 6.9 pEC50 7
pEC50 6.9 (EC50 1.2x10-7 M) [7]
belinostat Hs Inhibition 6.9 pEC50 7
pEC50 6.9 (EC50 1.25x10-7 M) [7]
entinostat Hs Inhibition 5.9 pEC50 7
pEC50 5.9 (EC50 1.155x10-6 M) [7]
santacruzamate A Hs Inhibition 9.9 pIC50 10
pIC50 9.9 (IC50 1.19x10-10 M) [10]
quisinostat Hs Inhibition 9.5 pIC50 1
pIC50 9.5 (IC50 3.3x10-10 M) [1]
CHR-3996 Hs Inhibition 8.4 pIC50 9
pIC50 8.4 (IC50 4x10-9 M) [9]
CUDC-907 Hs Inhibition 8.3 pIC50 11
pIC50 8.3 (IC50 5x10-9 M) [11]
CUDC-101 Hs Inhibition 7.9 pIC50 3
pIC50 7.9 (IC50 1.26x10-8 M) [3]
citarinostat Hs Inhibition 7.3 pIC50 6
pIC50 7.3 (IC50 4.5x10-8 M) [6]
ricolinostat Hs Inhibition 7.3 pIC50 12
pIC50 7.3 (IC50 4.8x10-8 M) [12]
BML-281 Hs Inhibition 6.6 pIC50 8
pIC50 6.6 (IC50 2.38x10-7 M) [8]
KA1010 Hs Inhibition 5.8 pIC50 4
pIC50 5.8 (IC50 1.542x10-6 M) [4]
butyric acid Hs Inhibition 4.9 pIC50 5
pIC50 4.9 (IC50 1.2x10-5 M) [5]
Inhibitor Comments
Vorinostat has high affinity for HDACs 2, 3, 6, 9, 10 and 11, but 10-fold lower affinity for HDAC8.
General Comments
HDAC2 is a Class I histone deacetylase.

References

Show »

1. Arts J, King P, Mariën A, Floren W, Beliën A, Janssen L, Pilatte I, Roux B, Decrane L, Gilissen R et al.. (2009) JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin. Cancer Res.15 (22): 6841-51. [PMID:19861438]

2. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R. (2010) Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol.6 (3): 238-243. [PMID:20139990]

3. Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C. (2010) Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J. Med. Chem.53 (5): 2000-9. [PMID:20143778]

4. Ellis JD, Neil DA, Inston NG, Jenkinson E, Drayson MT, Hampson P, Shuttleworth SJ, Ready AR, Cobbold M. (2016) Inhibition of Histone Deacetylase 6 Reveals a Potent Immunosuppressant Effect in Models of Transplantation. Transplantation100 (8): 1667-74. [PMID:27222932]

5. Fass DM, Shah R, Ghosh B, Hennig K, Norton S, Zhao WN, Reis SA, Klein PS, Mazitschek R, Maglathlin RL et al.. (2010) Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin. ACS Med Chem Lett2 (1): 39-42. [PMID:21874153]

6. Huang P, Almeciga-Pinto I, Jarpe M, van Duzer JH, Mazitschek R, Yang M, Jones SS, Quayle SN. (2016) Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models. Oncotarget,  [Epub ahead of print]. [PMID:27926524]

7. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N et al.. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J.409 (2): 581-9. [PMID:17868033]

8. Kozikowski AP, Tapadar S, Luchini DN, Kim KH, Billadeau DD. (2008) Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J. Med. Chem.51 (15): 4370-3. [PMID:18642892]

9. Moffat D, Patel S, Day F, Belfield A, Donald A, Rowlands M, Wibawa J, Brotherton D, Stimson L, Clark V et al.. (2010) Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. J. Med. Chem.53 (24): 8663-78. [PMID:21080647]

10. Pavlik CM, Wong CY, Ononye S, Lopez DD, Engene N, McPhail KL, Gerwick WH, Balunas MJ. (2013) Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J. Nat. Prod.76 (11): 2026-33. [PMID:24164245]

11. Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, Atoyan R, Qu H, Yin L, Samson M et al.. (2012) Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin. Cancer Res.18 (15): 4104-13. [PMID:22693356]

12. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC et al.. (2012) Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood119 (11): 2579-89. [PMID:22262760]

How to cite this page

3.5.1.- Histone deacetylases (HDACs): histone deacetylase 2. Last modified on 25/09/2017. Accessed on 16/12/2017. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2616.